Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer

Overview

Investigators aim to investigate whether circulating tumor DNA is a sensitive marker to evaluate patients' response to neoadjuvant chemotherapy

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 1, 2025

Detailed Description

Neoadjuvant chemotherapy(NAC) is traditionally for locally advanced disease, converting an inoperable to a resectable tumor.In recent years, it has become an option for patients of lower tumor stage to increase the possibility of breast conserving therapy. An effective method to monitor the response to NAC is important.

Clinical Trial Outcome Measures

Primary Measures

  • death of breast cancer
    • Time Frame: Follow-up time is estimated to be up to 5 years. The duration is from the date of diagnosis to date of death of breast cancer or date of death of any cause, whichever come first.
    • The event is defined as death of breast cancer, which is a separate measure

Secondary Measures

  • tumor recurrence or distant metastasis
    • Time Frame: Follow-up time is estimated to be up to 5 years.The duration is from diagnosis to local recurrence or distant metastasis of breast cancer. Patients were followed up every six months in first three years, then followed up once a year.
    • The event is defined as breast cancer local recurrence or distant metastasis

Participating in This Clinical Trial

Inclusion Criteria

  • Female patients undergoing NAC – Age: 18-70 yrs – Any menopausal status – Any hormal receptor status Exclusion Criteria:

  • Metastasis discovered during NAC – Lost more than 2 blood samples during NAC and surgery

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Liu Qiang, Professor – Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • Overall Official(s)
    • qiang Liu, Principal Investigator, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • Overall Contact(s)
    • Shunying Li, +86-15915939702, lishunying@foxmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.